A randomized controlled study for the efficacy and safety of endoscopic anti-reflux mucosectomy and endoscopic radiofrequency ablation in the treatment of refractory gastroesophageal reflux disease

A randomized controlled study for the efficacy and safety of anti-reflux mucosectomy and endoscopic radiofrequency ablation in the treatment of refractory gastroesophageal reflux disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022246

Enrollment

Unknown

Registered

2019-03-31

Start date

2019-04-10

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory gastroesophageal reflux disease

Interventions

Group1:endoscopic anti-reflux mucosectomy

Group2:endoscopic radiofrequency ablation

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed as refractory GERD (definition of refractory GERD patients: twice daily oral standard dose PPI = 8 weeks, symptom improvement <50%); 2) age 18-70 years; 3) tolerant general anesthesia .

Exclusion criteria

Exclusion criteria: 1) Potential bleeding disorders (gastric ulcer, acute gastritis); 2) Precancerous lesions or cancer; 3) Coagulopathy; 4) mental illness; 5) Pregnancy; 6) Esophageal erosion; 7) Esophageal varices; 8) Esophageal hiatus hernia> 2cm.

Design outcomes

Primary

Measure	Time frame
symptom;Esophageal manometry;Esophageal pH detection;Wound healing;	—

Countries

China

Contacts

Public ContactGuoxin Zhang

Jiangsu Provincial People's Hospital

guoxinz@njmu.edu.cn+86 13951913128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026